COMP <GO>
NUTX vs MA // ALTMAN Z-SCORE & DEBT/EQUITY
Nutex Health Inc. (NASDAQ) VS. Mastercard Incorporated (NYSE) • 15-METRIC TALLY: NUTX 6
— MA 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: MA
LAST: $210.10 (-1.19%) • MKT CAP: $1.44B
balance-sheet
3.75
LAST: $635.70 (+4.16%) • MKT CAP: $556.88B
balance-sheet
11.17
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUTX VS. MA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUTX | MA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | 33.50% | +51.50 | NUTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 4.6x | 29.2x | -24.60 | NUTX | /valuation <GO> |
| Free Cash Flow Yield | 17.07% | 3.08% | +13.99 | NUTX | /fcf-yield <GO> |
| Operating Margin | 31.50% | 57.60% | -26.10 | MA | /operating-margins <GO> |
| Net Profit Margin | 8.10% | 45.60% | -37.50 | MA | /net-margins <GO> |
| Revenue Growth (YoY) | 82.40% | 16.40% | +66.00 | NUTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | MA | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.75 | 11.17 | -7.42 | MA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | NUTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 68.8 | -22.12 | MA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.90 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.1x | 31.2x | -14.10 | NUTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.44B | $556.88B | -$555.44B | MA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUTX REV | MA REV | NUTX GROSS % | MA GROSS % | NUTX FCF | MA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $875.3M | $32.79B | 50.8% | — | $245.6M | $17.16B |
| FY 2024 | $479.9M | $28.17B | 40.9% | — | $20.8M | $14.31B |
| FY 2023 | $247.6M | $25.10B | — | — | $1.3M | $10.85B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUTX // BETA —
MA // BETA 0.90